Trianglebinimetinib (NCT04322383)
binimetinib trial for Hairy Cell Leukemia (NCT04322383). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with BRAF-wild-type hairy-cell leukemia or its variant, relapsed or refractory after a purine-analog treatment. Blood-count changes, symptoms or other progression criteria must establish a need for treatment. Moxetumomab access and treatment criteria also apply.
The idea: use binimetinib to block MEK1/2 growth signaling. A MEK mutation is not required. Patients take 45 milligrams twice daily in continuous 28-day cycles. Researchers measure responses; selected responders may try stopping therapy. Bone-marrow assessment is required.
This phase 2 study plans 40 patients. Robert Kreitman leads at NIH’s recruiting Bethesda site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.